Description of Research Expertise

breast cancer, biomarkers, clinical trials, pharmacogenetics, cytokines, host immunogenetics, cancer survivorship, molecular epidemiology

Selected Publications

Clark AS, Cobain EF, Dayao Z, Somerfield MR, DeMichele A, & Henry NL: Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update Q and A JCO Oncol Pract : 2022.

Thakran S, Cohen E, Jahani N, Weinstein S.P, Pantalone L, Hylton N, Newit D, DeMichele A, Davatzikos C, Kontos D.: Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial Transl Oncol. : 20:101411,2022.

Makhlin I, DeMichele A.: Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer Cell Rep Med. 3 (6): 100668,2022.

Makhlin I, & DeMichele A: Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer Cell Rep Med. 3 (6): 2022.

Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan, KM Sharma, P Shatsky, R Stringer-Reasor, E Telli, M Turner, N.C & DeMichele A.: Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update Journal of Clinical Oncology : 2022.

Cristofanilli M, Rugo H.S, Im S.A, Slamon D.J, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi S, Iwata H, O'Leary B, André F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Frean M.J, Turner N.C.: Overall Survival With Palbociclib And Fulvestrant in Women With HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-Blind, Phase 3 Randomized Study Clin Cancer Res. : 2022.

Brown J.C, Sturgeon K, Sarwer D.B, Troxel A.B, DeMichele A.M, Denlinger C.S, Schmitz K.H.: The effects of exercise and diet on sex steroids in breast cancer survivors Endocr Relat Cancer. : 2022.

Martei Y.M, Narasimhamurthy M, Setlhako D.I, Ayane G, Ralefala T, Chiyapo S, Gross R, Shulman L.N, Grover S, DeMichele A.: Relative Dose Intensity and Pathologic Response Rates in Patients With Breast Cancer and With and Without HIV Who Received Neoadjuvant Chemotherapy JCO Glob Oncol. : e2200016. ,2022.

Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo, J J, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz M, Cardoso F, Traina TA, , Sabanathan D, Breitenstein U, Ackerl K, Filho OM, Zehetner K, Solomon K, El-Abed S, Theall KP, Ray-Lu D, Dueck A, Gnant M, DeMichele A.: Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03) J Clin Oncol. 10 (40): 449-458,2022.

Cescon DW, Kalinsky K, Parsons HA, Smith KL, Spears PA, Thomas A, Zhao F & DeMichele A: Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches Front Oncol. 11 (10): 2022.

Academic Contact Information

Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-153
3400 Civic Center Boulevard
Philadelphia, PA 19104
Phone: 215-349-5730
Patient appointments: 800-789-7366